PROGENICS PHARMACEUTICALS INC
PROGENICS PHARMACEUTICALS INC (PGNX): 4 pipeline candidates · ~13 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
12.9 months
D/E 2.21
Lead: Approved
4 candidates
N/A
N/A
A transparent, data-derived signal for PROGENICS PHARMACEUTICALS INCacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$29.5M
Quarterly Burn
$7.6M
Runway
12.9 mo
Revenue
$6.2M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (4 candidates)
| Drug | Phase |
|---|---|
| azedra | Approved |
| i-131-1095 | Phase 2 |
| pylarify | Approved |
| pylarify | Approved |
Frequently asked questions
How many drug candidates are in PROGENICS PHARMACEUTICALS INC's pipeline?
PROGENICS PHARMACEUTICALS INC (PGNX) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is PROGENICS PHARMACEUTICALS INC's lead drug candidate?
PROGENICS PHARMACEUTICALS INC's most advanced tracked candidate is azedra (Approved) for iodine-based products.
What is PROGENICS PHARMACEUTICALS INC's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, PROGENICS PHARMACEUTICALS INC has approximately 12.9 months of cash runway.
Get the full picture on PROGENICS PHARMACEUTICALS INC
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.